Development and characterization of a novel cationic PEGylated niosome-encapsulated forms of doxorubicin, quercetin and siRNA for the treatment of cancer by using combination therapy

References

• Saadat S, Yousefifard M, Asady H, et al. The most important causes of death in Iranian population; a retrospective cohort study. Emergency. 2015;3:16–21.
   PubMed Web of Science ®Google Scholar
• Dry JR, Yang M, Saez-Rodriguez J. Looking beyond the cancer cell for effective drug combinations. Genome Med. 2016;8:125.
   PubMed Web of Science ®Google Scholar
• Gandhi NS, Tekade RK, Chougule MB. Nanocarrier mediated delivery of siRNA/miRNA in combination with chemotherapeutic agents for cancer therapy: current progress and advances. J Control Release. 2014;194:238–256.
   PubMed Web of Science ®Google Scholar
• Xu B, Jin Q, Zeng J, et al. Combined tumor- and neovascular-“dual targeting” gene/chemo-therapy suppresses tumor growth and angiogenesis. ACS Appl Mater Interfaces. 2016;8:25753–25769.
   PubMed Web of Science ®Google Scholar
• Shah N, Chaudhari K, Dantuluri P, et al. Paclitaxel-loaded PLGA nanoparticles surface modified with transferrin and Pluronic® P85, an in vitro cell line and in vivo biodistribution studies on rat model. J Drug Target. 2009;17:533–542.
   PubMed Web of Science ®Google Scholar
• Refolo MG, D'Alessandro R, Malerba N, et al. Anti proliferative and pro apoptotic effects of flavonoid quercetin are mediated by CB1 receptor in human colon cancer cell lines. J Cell Physiol. 2015;230:2973–2980.
   PubMed Web of Science ®Google Scholar
• Srivastava S, Somasagara RR, Hegde M, et al. Quercetin, a natural flavonoid interacts with DNA, arrests cell cycle and causes tumor regression by activating mitochondrial pathway of apoptosis. Sci Rep. 2016;6:24049.
   PubMed Web of Science ®Google Scholar
• Dong Q, Chen L, Lu Q, et al. Quercetin attenuates doxorubicin cardiotoxicity by modulating Bmi-1 expression. Br J Pharmacol. 2014;171:4440–4454.
   PubMed Web of Science ®Google Scholar
• Pappou EP, Ahuja N. The Role of oncogenes in gastrointestinal cancer. J Gastrointest Dig Syst. 2013(Suppl 1):S2–S15.
   Google Scholar
• Weinstein J, Jacobsen FW, Hsu-Chen J, et al. A novel mammalian protein, p55CDC, present in dividing cells is associated with protein kinase activity and has homology to the Saccharomyces cerevisiae cell division cycle proteins Cdc20 and Cdc4. Mol Cell Biol. 1994;14:3350–3363.
   PubMed Web of Science ®Google Scholar
• Kim JM, Sohn HY, Yoon SY, et al. Identification of gastric cancer-related genes using a cDNA microarray containing novel expressed sequence tags expressed in gastric cancer cells. Clin Cancer Res. 2005;11:3149–3482.
   Web of Science ®Google Scholar
• Ding ZY, Wu HR, Zhang JM, et al. Expression characteristics of CDC20 in gastric cancer and its correlation with poor prognosis. Int J Clin Exp Pathol. 2014;7:722–727.
   PubMed Web of Science ®Google Scholar
• Kanasty RL, Whitehead KA, Vegas AJ, et al. Action and reaction: the biological response to siRNA and its delivery vehicles. Mol Ther. 2012;20:513–524.
   PubMed Web of Science ®Google Scholar
• Whitehead KA, Langer R, Anderson DG. Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov. 2009;8:129–138.
   PubMed Web of Science ®Google Scholar
• Nematollahi MH, Torkzadeh-Mahanai M, Pardakhty A, et al. Ternary complex of plasmid DNA with NLS-Mu-Mu protein and cationic niosome for biocompatible and efficient gene delivery: a comparative study with protamine and lipofectamine. Artif Cells Nanomed Biotechnol. 2017;1–11.
   PubMed Web of Science ®Google Scholar
• Haghiralsadat F, Amoabediny G, Helder MN, et al. A comprehensive mathematical model of drug release kinetics from nano-liposomes, derived from optimization studies of cationic PEGylated liposomal doxorubicin formulations for drug-gene delivery. Artif Cells Nanomed Biotechnol. 2018;46:169–177.
   PubMed Web of Science ®Google Scholar
• Mokhtar M, Sammour OA, Hammad MA, et al. Effect of some formulation parameters on flurbiprofen encapsulation and release rates of niosomes prepared from proniosomes. Int J Pharm. 2008;361:104–111.
   PubMed Web of Science ®Google Scholar
• Junyaprasert VB, Singhsa P, Suksiriworapong J, et al. Physicochemical properties and skin permeation of Span 60/Tween 60 niosomes of ellagic acid. Int J Pharm. 2012;423:303–311.
   PubMed Web of Science ®Google Scholar
• Ruckmani K, Sankar V. Formulation and optimization of Zidovudine niosomes. AAPS PharmSciTech. 2010;11:1119–1127.
   PubMed Web of Science ®Google Scholar
• Arzani G, Haeri A, Daeihamed M, et al. Niosomal carriers enhance oral bioavailability of carvedilol: effects of bile salt-enriched vesicles and carrier surface charge. Int J Nanomed. 2015;10:4797–4813.
   PubMed Web of Science ®Google Scholar
• El-Samaligy MS, Afifi NN, Mahmoud EA. Increasing bioavailability of silymarin using a buccal liposomal delivery system: preparation and experimental design investigation. Int J Pharm. 2006;308:140–148.
   PubMed Web of Science ®Google Scholar
• Patel HM. Liposomes: a practical approach. FEBS Lett. 1990;275:242–243.
   Google Scholar
• Pawlikowska-Pawlęga B, Dziubińska H, Król E, et al. Characteristics of quercetin interactions with liposomal and vacuolar membranes. Biochim Biophys Acta. 2014;1838:254–265.
   PubMed Web of Science ®Google Scholar
• Li J, Wang X, Zhang T, et al. A review on phospholipids and their main applications in drug delivery systems. Asian J Pharm Sci. 2015;10:81–98.
   Web of Science ®Google Scholar
• Li Y, Pei Y, Zhang X, et al. PEGylated PLGA nanoparticles as protein carriers: synthesis, preparation and biodistribution in rats. J Control Release. 2001;71:203–211.
   PubMed Web of Science ®Google Scholar
• Kim JY, Kim JK, Park JS, et al. The use of PEGylated liposomes to prolong circulation lifetimes of tissue plasminogen activator. Biomaterials. 2009;30:5751–5756.
   PubMed Web of Science ®Google Scholar
• Wang AZ, Gu F, Zhang L, et al. Biofunctionalized targeted nanoparticles for therapeutic applications. Expert Opin Biol Ther. 2008;8:1063–1070.
   PubMed Web of Science ®Google Scholar
• Gang W, Jie WJ, Ping ZL, et al. Liposomal quercetin: evaluating drug delivery in vitro and biodistribution in vivo. Expert Opin Drug Deliv. 2012;9:599–613.
   PubMed Web of Science ®Google Scholar
• Verhoef JJF, Anchordoquy TJ. Questioning the use of PEGylation for drug delivery. Drug Deliv Transl Res. 2013;3:499–503.
   PubMed Web of Science ®Google Scholar
• Yang BB, Lum PK, Hayashi MM, et al. Polyethylene glycol modification of filgrastim results in decreased renal clearance of the protein in rats. J Pharm Sci. 2004;93:1367–1373.
   PubMed Web of Science ®Google Scholar
• Swietach P, Vaughan-Jones RD, Harris AL, et al. The chemistry, physiology and pathology of pH in cancer. Philos Trans R Soc B Biol Sci. 2014;369:20130099.
   PubMed Web of Science ®Google Scholar
• Lee RJ, Wang S, Turk MJ, et al. The effects of pH and intraliposomal buffer strength on the rate of liposome content release and intracellular drug delivery. Biosci Rep. 1998;18:69–78.
   PubMed Web of Science ®Google Scholar
• Naderinezhad S, Amoabediny G, Haghiralsadat F. Co-delivery of hydrophilic and hydrophobic anticancer drugs using biocompatible pH-sensitive lipid-based nano-carriers for multidrug-resistant cancers [10.1039/C7RA01736G]. RSC Adv. 2017;7:30008–30019.
   Web of Science ®Google Scholar
• Sezgin-Bayindir Z, Onay-Besikci A, Vural N, et al. Niosomes encapsulating paclitaxel for oral bioavailability enhancement: preparation, characterization, pharmacokinetics and biodistribution. J Microencapsul. 2013;30:796–804.
   PubMed Web of Science ®Google Scholar
• Tavano L, Muzzalupo R, Picci N, et al. Co-encapsulation of antioxidants into niosomal carriers: gastrointestinal release studies for nutraceutical applications. Colloids Surf B Biointerfaces. 2014;114:82–88.
   PubMed Web of Science ®Google Scholar
• Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010;70:440–446.
   PubMed Web of Science ®Google Scholar
• Li N, Sun C, Zhou B, et al. Low concentration of quercetin antagonizes the cytotoxic effects of anti-neoplastic drugs in ovarian cancer. PLoS One. 2014;9:e100314
   PubMed Web of Science ®Google Scholar
• Samuel T, Fadlalla K, Mosley L, et al. Dual-mode interaction between quercetin and DNA-damaging drugs in cancer cells. Anticancer Res. 2012;32:61–71.
   PubMed Web of Science ®Google Scholar